Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint summarizes currently available therapeutics for nonhospitalized patients in the setting of the Omicron variant including principles for equitable allocation. Patients with mild or moderate COVID-19 are those who have respiratory and systemic
Researchers from Canada and United States co-lead study of children to learn more about risk factors for severe outcomes Anew international study offers a clearer picture of the impact of COVID-19 infection and the risk of severe outcomes on young people around the world. The study was co-led by a team of researchers from
A human induced pluripotent stem cell colony from OCA1A patient. The image was acquired using a confocal microscope and is stained for pluripotency marker proteins. The red color depicts transcription factor OCT4, green is SSEA4 protein and blue represents the nucleus of the cells.NEI “Animals used to study albinism are less than ideal because they
Interleukin-12 (IL12) is a pleiotropic cytokine with promising prospects for cancer immunotherapy. Though IL12 gene-based therapy could overcome the fatal hurdle of severe systemic toxicity, targeted delivery and tumor-located expression of IL12 gene remain the challenging issues yet to be solved. Photo-immunotherapy emerging as a novel and precise therapeutic strategy, which elaborately combines immune-activating agents
In the ZUMA-7 trial, at a median follow-up of 24.9 months, patients randomly assigned to receive CAR T-cell therapy with axicabtagene ciloleucel, or axi-cell (Yescarta) had a median event-free survival (EFS) of 8.3 months, compared with 2 months for patients randomly assigned to standard-of-care chemoimmunotherapy, reported Frederick L. Locke, MD, from the Moffitt Cancer Center
The FDA has approved 28 of the more than 1,000 such diagnostics commercially available worldwide. In brief: A clinical practice article in the New England Journal of Medicine distills available data and clinical experience into a compendium about rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The appendix identified nearly all FDA-approved rapid diagnostic tests and
A study published by researchers at the University of Illinois Chicago describes a new method for analyzing pyroptosis — the process of cell death that is usually caused by infections and results in excess inflammation in the body — and shows that process, long thought to be irreversible once initiated, can in fact be halted
A new study conducted by Japanese researchers has shown that peak viral loads in people infected with omicron occur between 3 to 6 days after the onset of symptoms. The study raises further concerns about the CDC cutting the self-isolating time for people with Covid-19 to 5 days, not 10. The report was published online on January
Removing one type of T cell from donor blood used for stem cell grafts could greatly reduce a serious complication called graft-versus-host disease in patients with leukemia, according to a new study. Published today in the Journal of Clinical Oncology, the study reports that only 7% of leukemia patients who received stem cell transplants depleted of
Penn study reveals an easier, more scalable way to make a powerful immunotherapy An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine
